Type 1 diabetes is a chronic disease that can be hard to treat. With this form of diabetes, your body’s immunity attacks and destroys beta cells, which produce insulin. The body’s natural ability to make insulin prevents glucose in the bloodstream from being absorbed and used as energy by cells. Patients with type 1 diabetics need to take insulin for the rest of their lives, either via an injection or pump. It is not necessary for type 1 diabetes to develop in childhood. 1.7 million adults aged 20 or older – or 5.7% of U.S. adults – have the disease and are receiving insulin via shots or a pump.
The global market to treat type 1 diabetes currently stands at $16,97 billion, and is projected to grow by 6.9% between now and 2032.
Image credit: Shutterstock
Biodexa believes it has the answer
This is why some companies have taken the initiative to do so. Biodexa Pharmaceuticals PLC BDRXThis insidious illness is being treated by, an advanced biopharmaceutical firm that develops treatments to meet unmet medical need. Biodexa, which is working on Tolimidone for type 1 diabetes treatment, has just enrolled the first patient into a phase-2a trial.
Tolimidone is a drug that was discovered in Pfizer Inc. PFE It was designed to treat ulcers of the stomach. Pfizer discontinued the development of this drug due to its lack of effectiveness for gastric Ulcers. Tolimidone has promise for those with type 1 diabetes. It is a select activator of Lyn Kinase which enhances the phosphorylation insulin substrate-1. This means that it could potentially aid the body in producing insulin. Lyn belongs to the Src protein tyrosine-kinases family. It is mostly expressed in hematopoietic and neural cells as well as in liver, adipose, and liver tissue.
In a series of preclinical trials conducted by the University of Alberta, Tolimidone was shown to be effective in treating type 1 diabetes. These studies revealed that Lyn Kinase is a critical factor in beta cell proliferation and survival. In vitro The following are some examples of how to get started: in vivo models, reports Biodexa. Very promising, noted the company, is the fact that Tolimidone was able to induce proliferation in beta cells isolated from human cadavers. Biodexa is confident that the drug could become the first of its kind to modulate blood sugar. It would be a welcome development for patients with type 1 diabetes who must take insulin or use an implantable insulin pump. Even a single pill can be a game changer for type 1 diabetes patients who are forced to use insulin pumps or take shots of insulin.
This is the first Phase 2a patient.
Biodexa and the University of Alberta are currently working on a phase 2-a dose-confirmation study. The enrollment of the study’s first participant is an important milestone for Biodexa. Health Canada had already approved this study, which is being conducted by University of Alberta. It will evaluate C-peptides (a marker of insulin) and blood glucose levels HbA1c after 3 months in comparison to the baseline. This study could be extended.
Stephen Stamp (CEO and CFO of Biodexa) said at the time of the first announcement of the study: “We’re excited to launch our clinical programme in type 1 diabetics with the University of Alberta. We will build on an extensive tolimidone package of data put together Pfizer Melior Bukwang.”. This study builds on preclinical evidence that Tolimidone may have an impact on insulin-producing beta cells in the pancreas.
Type 1 Diabetes is not as common, but the effects can be life changing. Patients are dependent on insulin the rest of their days. Biodexa wants to help patients by taking an already-developed drug and using it in a new form. The company thinks this has a great deal of potential.
Biodexa has a step closer to providing relief for type 1 diabetics with the enrollment of its first patient in phase 2a. Keep an eye out for more information about Tolimidone’s and Biodexa’s progress against a disease affecting millions in the U.S.
Biodexa is the source of this image.
The content of this post is sponsored. The content on this page is intended for informational use only, and not as investment advice.
Biodexa pharmaceuticals: Click Here for More Information
Please read this important noticeInformation and statistics contained in this document may include forward-looking statements. These are statements about the intentions, beliefs, assumptions or expectations of a company regarding future events. This includes, but is not limited to: expectations with regard to FDA approval and other regulatory agencies, product technology and milestones of product development, ability to leverage product development, negotiate favorable collaboration agreements, sales commencing, market potential for the product candidates of a company, cash flow sufficient to meet future capital and liquidity needs, as well as other risks identified by the SEC’s Risk Factor This information may change at any time. We are not obligated to inform you of changes. Forward-looking information is qualified by factors that may cause results to be materially different from what was projected. The timing and amount of milestone payments, as well as the costs and expenditures related to a company’s R&D programs can also cause significant changes in quarterly results. It is not intended to be a solicitation or offer of purchase or sale. Redington, Inc. receives a fee from Biodexa Pharmaceutics PLC for investor relations and employees of the company or their family members may own equity interests in some companies.